THE WHAT? Pola Orbis has announced FY2021 net sales rise of 1.3 percent YOY to ¥178,642.
THE DETAILS Operating income was up 22.8 percent to ¥16,888 yen, up from ¥13,752 FY2020 with shareholders seeing a 6.9 percent return on equity, up from 2.6 percent in 2020.
Looking at each category. Beauty Care operating results rose 1.5 percent to ¥174,150.
According to a press release, “Pola is seeking to further improve the value of its brand and establish its customer foundation over the medium to long term, through efforts to launch highly functional products mainly in the field of anti-aging and skin- brightening, and to focus on the growth markets of China and travel retail.
“In the domestic business, POLA has worked to strengthen online consulting in the e-commerce business, which is rapidly growing, as a measure to improve communication during the COVID-19 pandemic.”
THE WHY? Pola focused heavily on the pandemic when reviewing its financial results, stating, “During the fiscal year ended December 31, 2021 (January 1–December 31, 2021), the Japanese economy suffered unavoidable restrictions on economic activities. This was due to the spread and prolongation of COVID-19 (the novel coronavirus), which led to declarations of a state of emergency and applications of quasi-emergency measures.”
The company highlighted that consumption had declined in the domestic cosmetics market due to the collapse of inbound demand as a result of COVID-19.
Pola said, “In the overseas cosmetics market, there was a general trend toward recovery from the decline caused by COVID-19, with variations in each country or region.”
However, it noted that from the end of 2021 until now, new cases of the virus have increased rapidly, so the situation has become more severe.
“Within this market environment, the POLA ORBIS Group has worked to achieve the key objectives – “evolving domestic direct sales,” “growing overseas businesses profitably,” “profit contribution from brands under development,” “strengthening operations,” and “expanding new brands and domains of ‘beauty’.”
Aesthetic injectable companies refer to businesses or companies that specialize in manufacturing, distributing, or providing aesthetic injectable products and services. These companies focus on developing and supplying injectable substances used for cosmetic purposes, typically administered by qualified medical professionals. Aesthetic injectable companies play a crucial role in the field of aesthetic medicine and cosmetic dermatology by offering a variety of injectable products designed to enhance facial features, reduce wrinkles, and improve overall skin appearance.
Key aspects of aesthetic injectable companies include:
-
Product Development: These companies research, develop, and manufacture aesthetic injectables such as dermal fillers, botulinum toxins (e.g., Botox), collagen stimulators, and other specialized formulations. They often innovate new products to meet evolving market demands and technological advancements.
-
Distribution and Sales: Aesthetic injectable companies distribute their products through authorized channels, including healthcare providers, medical spas, and aesthetic clinics. They may also sell directly to licensed professionals who administer these treatments.
-
Regulatory Compliance: Due to the medical nature of their products, aesthetic injectable companies adhere to strict regulatory guidelines and obtain necessary approvals from health authorities (e.g., FDA in the United States) to ensure safety, efficacy, and quality standards.
-
Training and Support: Many companies provide training and educational support to healthcare professionals on the proper use, administration techniques, and safety protocols associated with their injectable products. This ensures that practitioners can deliver treatments effectively and safely.
-
Customer Support: Aesthetic injectable companies offer customer support services to healthcare providers and consumers, addressing inquiries, providing product information, and assisting with product usage and troubleshooting.
